Marfan Syndrome type II
Marfan Syndrome type II (also known as Marfanoid–hypermobility spectrum disorder) is a genetic disorder that affects the body's connective tissue. Connective tissue provides strength and flexibility to structures such as bones, ligaments, muscles, blood vessels, and heart valves.
Symptoms[edit | edit source]
The symptoms of Marfan Syndrome type II can vary greatly in severity, timing of onset, and the organs affected. Symptoms can include tall stature, joint hypermobility, heart defects, and eye abnormalities. Some people with the disorder have only mild symptoms, while others have severe and life-threatening complications.
Causes[edit | edit source]
Marfan Syndrome type II is caused by mutations in the FBN1 gene. This gene provides instructions for producing a protein called fibrillin-1. Fibrillin-1 is an essential component of microfibrils, which provide strength and flexibility to connective tissue. Mutations in the FBN1 gene disrupt the production or function of fibrillin-1, leading to the signs and symptoms of Marfan Syndrome type II.
Diagnosis[edit | edit source]
Diagnosis of Marfan Syndrome type II is based on clinical criteria, or the Ghent criteria, which consider the individual's family history, physical symptoms, and the results of a genetic test. A diagnosis can be confirmed with a positive genetic test for mutations in the FBN1 gene.
Treatment[edit | edit source]
There is currently no cure for Marfan Syndrome type II. Treatment is aimed at managing the symptoms and preventing complications. This can include medications to slow the rate of aortic enlargement and prevent aortic dissection, surgery to repair the aorta, and physical therapy to manage joint pain.
Prognosis[edit | edit source]
The prognosis for individuals with Marfan Syndrome type II can vary greatly depending on the severity of symptoms. With appropriate management, most people with the disorder have a normal lifespan.
See also[edit | edit source]
NIH genetic and rare disease info[edit source]
Marfan Syndrome type II is a rare disease.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
